Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer”

33 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 33 results

Large-scale testing (Phase 3)Active Not RecruitingNCT05306340
What this trial is testing

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Who this might be right for
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Genentech, Inc. 373
Large-scale testing (Phase 3)Study completedNCT01626222
What this trial is testing

4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 301
Early research (Phase 1)Looking for participantsNCT07214662
What this trial is testing

Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 136
Large-scale testing (Phase 3)Study completedNCT03176238
What this trial is testing

Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Post Menopausal Breast Cancer
Novartis Pharmaceuticals 235
Testing effectiveness (Phase 2)Study completedNCT01151046
What this trial is testing

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Who this might be right for
Her2 Negative Breast Cancer Patients
Merrimack Pharmaceuticals 118
Large-scale testing (Phase 3)Looking for participantsNCT07062965
What this trial is testing

Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Who this might be right for
Breast Cancer
Pfizer 400
Large-scale testing (Phase 3)Ended earlyNCT01303679
What this trial is testing

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Who this might be right for
First Line Metastatic Breast Cancer
ARCAGY/ GINECO GROUP 117
Early research (Phase 1)Ended earlyNCT05080842
What this trial is testing

AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 21
Testing effectiveness (Phase 2)Looking for participantsNCT07100106
What this trial is testing

Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 285
Large-scale testing (Phase 3)Looking for participantsNCT06760637
What this trial is testing

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Who this might be right for
Breast Cancer
Pfizer 1,020
Testing effectiveness (Phase 2)Active Not RecruitingNCT04576455
What this trial is testing

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Who this might be right for
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche 303
Testing effectiveness (Phase 2)Looking for participantsNCT06428396
What this trial is testing

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

Who this might be right for
Metastatic Breast Cancer
Merck Sharp & Dohme LLC 120
Large-scale testing (Phase 3)Active Not RecruitingNCT04975308
What this trial is testing

Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Who this might be right for
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company 874
Testing effectiveness (Phase 2)UnknownNCT04669587
What this trial is testing

ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)

Who this might be right for
Estrogen Receptor-PositiveHER2-NegativeLocally Advanced Breast Cancer+1 more
EnhancedBio USA Inc. 106
Testing effectiveness (Phase 2)Study completedNCT03312738
What this trial is testing

Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 159
Testing effectiveness (Phase 2)Ended earlyNCT04059484
What this trial is testing

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

Who this might be right for
Breast Cancer Metastatic
Sanofi 367
Testing effectiveness (Phase 2)Study completedNCT03250676
What this trial is testing

Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

Who this might be right for
Breast NeoplasmsBreast CancerEstrogen-receptor Positive Breast Cancer+5 more
Eisai Inc. 151
Early research (Phase 1)Study completedNCT01281150
What this trial is testing

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Adult Solid NeoplasmEstrogen Receptor NegativeEstrogen Receptor Positive+8 more
National Cancer Institute (NCI) 22
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07173556
What this trial is testing

A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Qilu Pharmaceutical Co., Ltd. 96
Testing effectiveness (Phase 2)Study completedNCT01698918
What this trial is testing

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast Cancer
Novartis Pharmaceuticals 202
Load More Results